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Saponin-based adjuvants induce cross-presentation
in dendritic cells by intracellular lipid body
formation
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Saponin-based adjuvants (SBAs) are being used in animal and human (cancer) vaccines, as
they induce protective cellular immunity. Their adjuvant potency is a factor of inﬂammasome
activation and enhanced antigen cross-presentation by dendritic cells (DCs), but how
antigen cross-presentation is induced is not clear. Here we show that SBAs uniquely induce
intracellular lipid bodies (LBs) in the CD11bþ DC subset in vitro and in vivo. Using genetic
and pharmacological interference in models for vaccination and in situ tumour ablation,
we demonstrate that LB induction is causally related to the saponin-dependent increase in
cross-presentation and T-cell activation. These ﬁndings link adjuvant activity to LB formation,
aid the application of SBAs as a cancer vaccine component, and will stimulate development of
new adjuvants enhancing T-cell-mediated immunity.
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A
djuvants are diverse compounds that enhance the
effectiveness of (cancer) vaccines. For human vaccines,
registered adjuvants are limited and include aluminum-
based and oil/water-based adjuvants. These adjuvants induce
robust antibody responses, but weak cell-mediated immunity,
which is crucial for application in anti-cancer vaccines.
Saponin-based adjuvants (SBAs) are promising new adjuvants
that enhance T-cell-mediated immunity.
Saponins are a large family of amphipathic plant glycosides,
structurally sharing a lipophilic triterpene derivative. By
puriﬁcation of the raw plant material, fractions with distinct
immunostimulatory properties and safety proﬁles have been
identiﬁed1. Although most saponins have strong binding
afﬁnity for cholesterol, only some stimulate the immune
system2. Forty nanometer cage-like particles called immune
stimulatory complexes (ISCOMs) form when immunoactive
saponin, cholesterol and phospholipid are brought together and
dialysed3. The physical properties of ISCOM adjuvants contribute
to its stability, and reduce the haemolytic effects associated with
saponins. SBAs stimulate strong innate and adaptive cellular
immunity, and elicit humoral responses of all IgG isotypes with a
mixed Th1/Th2 balance4–6. By contrast, aluminum-based or
oil/water-based adjuvants predominantly drive Th2 responses.
Th1 responses are particularly vital for the clearance of viral
infections, but also for the eradication of cancer7.
SBAs are now being applied in human vaccines, and several
clinical trials have proven safety and efﬁcacy4,5,8–9. Next to viral
antigens (for example, H5N1), SBAs have been shown to facilitate
responses to cancer antigens10. We previously demonstrated
in our model of in situ tumour ablation that co-injection of
SBAs induced superior anti-tumour immunity relative to other
adjuvants11. This unique effect was accompanied by high
numbers of cytotoxic T cells (CTL) speciﬁc for antigens in the
ablated tumour material. Vaccination with NY-ESO-1 (ref. 12)
or MAGE13 tumour antigens formulated in SBAs, induced strong
humoral and T-cell-mediated immune responses in melanoma
patients, leading to reduced relapse rates. Cebon and co-workers
combined SBA vaccination with low doses of cyclophosphamide
to deplete Treg cells, resulting in signiﬁcantly increased T-cell
responses in these patients14. These ﬁndings, and the improving
safety proﬁle of SBAs15, place SBAs at the forefront of current
anti-cancer vaccine research.
Despite the growing need to understand how vaccines work,
the exact immunological mechanisms of many classical immune
adjuvants are not well deﬁned. Wilson et al.16 demonstrated the
involvement of the NLRP3 inﬂammasome and IL-18 production
in ISCOM-mediated vaccine efﬁcacy; however, this ﬁnding
does not fully explain why ISCOMs stand out from other
adjuvants that trigger the inﬂammasome (for example, Al(OH)3).
Dendritic cells (DCs) have a critical role in the in vivo
effectiveness of SBA-aided vaccines, and enhanced antigen
cross-presentation by DCs has been reported to be particularly
important for the ability of SBAs to induce cellular CD8þ
T-cell immunity17. Two main intracellular pathways for the
cross-presentation of exogenous antigens have been proposed,
referred to as the ‘cytosolic’ and ‘vacuolar’ pathways18. In the
cytosolic cross-presentation pathway, internalized proteins are
slowly degraded in endosomal compartments by enzymatic
digestion at acidic pH. By unknown mechanisms the antigens
gain access to the cytosol where they are further degraded in a
proteasome dependent manner. Peptides generated this way can
then enter the classical MHC-I presentation route. By contrast,
cross-presentation through the vacuolar pathway is proteasome
independent, but sensitive to blockade of lysosomal proteolysis.
Antigen processing and loading on MHC-I therefore occurs
in endocytic compartments only. Cross-priming will only occur
in DCs matured by interaction with pathogen-associated
molecular patterns or CD4þ T helper cells19. Next to
activation status, the sub-class of DC is also of importance.
DCs can be classiﬁed as conventional DCs (cDCs), plasmacytoid
DCs (pDCs) or monocyte-derived DCs20. cDCs are located in
lymphoid and non-lymphoid tissues and can be further
classiﬁed into two ontogenetically distinct subtypes: the
CD8aþ /CD103þ DCs and the CD11bþ DCs21,22. In vivo
studies suggest that cross-presentation is typically performed
by the CD8aþ /CD103þ subset of cDCs23,24; however, under
speciﬁc conditions every other subtype is capable of cross-
presentation25. For instance, in an inﬂammatory environment
in vivo CD11bþ monocyte-derived DCs efﬁciently cross-present
OVA protein expressed by Escherichia coli (ref. 26). In
our tumour models, SBAs trigger an unprecedented level of
cross-presentation11, but how SBAs steer this process is
unknown.
Lipid body (LB) organelles consist of a phospholipid
monolayer that surrounds a core of neutral lipids, such as sterol
esters or triacylglycerols. The monolayer contains numerous
proteins, many with unknown function27. Enzymes of lipid
metabolism (for example, diacylglycerol acyltransferase, DGAT),
LB membrane proteins (for example, adipose differentiation-
related protein, ADRP28), and ER proteins (for example, the p47
GTPase IGTP) have been identiﬁed in LB fractions29,30. Ralph
Steinman made note of LBs in his seminal 1973 manuscript
describing the dendritic cell, but their function in immune cells is
only just starting to be explored31,32.
Our data now uncover an essential link between LBs and
cross-presentation in the working mechanism of SBA adjuvants
occurring uniquely in the CD11bþ DC subset. Genetic or
pharmacological blockade of LB induction effectively abrogates
the SBA-induced antigen cross-presentation, in a vaccination
setting as well as an in situ tumour ablation model. Mechanistic
studies suggest that SBAs induce LBs independent of
SBA-triggered antigen translocation, and that LBs facilitate
the proteasomal route of cross-presentation. These data
highlight the importance of lipid body induction in CD11bþ
DC for SBA vaccine activity, will aid SBA vaccine development,
and the design of new adjuvants enhancing T-cell-mediated
immunity.
Results
Saponin-based adjuvants induce cross-presentation in DCs.
SBAs induce potent immune responses to a broad repertoire of
antigens. SBAs and antigen can just be ad-mixed without prior
complexation or formulation4,5, or simply be injected in an ablated
tumour to boost antigen-speciﬁc CD8þ T-cell responses
(Fig. 1a,b)11. In an ablation setting, the tumour debris that stays
inside the body following treatment provides an effective source of
(neo)antigens for processing by the immune system33,34. The
induction of potent CD8þ T-cell responses is dependent on the
ability of SBAs to facilitate cross-presentation of exogenous
antigens in MHC-I by DCs5,35,36. How SBAs act to induce
antigen cross-presentation is poorly understood. By testing a panel
of classical non-microbial vaccine adjuvants, we ﬁrst conﬁrmed
that the saponin containing ISCOM Matrix C induced a dramatic
increase in ovalbumin (OVA) antigen cross-presentation in
GM-CSF-propagated DCs (Fig. 1c; Supplementary Fig. 1a). As a
read out system, we used either the co-stimulation independent
B3Z reporter T-cell line29, or OVA-speciﬁc T cells from OT-I
transgenic mice. None of the other non-microbial vaccine
adjuvants was able to induce cross-presentation of OVA in DCs
(Fig. 1d). The low amount of OVA used did not by itself lead to
detectable cross-presentation in DCs in our assays (Fig. 1d), and
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MHC-II-restricted antigen presentation of OVA to OT-II cells was
not altered by SBA administration (Supplementary Fig. 1b).
Only very distinct saponin fractions show immunological
activity and qualify as vaccine adjuvant. So far, most SBA
cross-presentation studies have been performed using proprietary
made ISCOM structures17,35,37–39. Therefore, we tested whether
different immune activating saponin fractions exhibited the same
capacity to induce cross-presentation. All three commercially
available fractions tested, and the corresponding ISCOMs
made from two of these fractions according to an open-access
protocol (Supplementary Fig. 2 and ref. 40) led to efﬁcient
increases in cross-presentation (Fig. 1e). In contrast, a saponin
mixture not enriched for immuno-active fractions (crude
saponin) did not induce cross-presentation, also at higher
concentrations (Fig. 1e). Importantly, SBA treatment did not
lead to reduced cell viability or MHC-I levels on the surface of the
APCs, as presentation of pulsed peptide was intact in all occasions
(Fig. 1e; Supplementary Fig. 3). Finally, we conﬁrmed that within
the ISCOMs the saponins are the cross-presentation inducing
moiety, and not the ISCOM-stabilizing component cholesterol
(Supplementary Fig. 4).
Cross-presentation induction in DCs thus is a feature shared by
immunoactive saponins, but not by other saponins.
SBA-induced cross-presentation is co-stimulation independent.
The increases in cross-presentation could not be explained by
differential surface expression of the mannose receptor (CD206,
involved in uptake of OVA), or MHC-I/II (Fig. 2a), and consistent
with literature, SBAs also did not change CD80 or CD86 levels on
the in vitro cultured DCs (Fig. 2b)17. Together with the fact that
B3Z cells react co-stimulation independent, this indicated that
maturation status of the DCs is not causing the observed increases
in cross-presentation. In line with this, BMDCs from Tlr4 / ,
Myd88 / or Trif / mice all had an intact ability to cross-
present OVA following ISCOMs treatment (Fig. 2c). Moreover,
also the type I IFN receptor or the inﬂammasome component
NLRP3 did not affect SBA-aided cross-presentation (Fig. 2c).
Antigen uptake or overall antigen processing by GM-CSF DCs, as
measured by the internalization of ﬂuorescent OVA or breakdown
of DQ-OVA, was not altered following SBA treatment (Fig. 2d).
We conclude that the increases in cross-presentation induced
by SBAs in DCs are antigen uptake or co-stimulation
independent.
Endosomal ROS is not involved in cross-presentation by SBAs.
As previous work has implicated a role for reactive oxygen species
(ROS) produced by the phagosomal NADPH-oxidase (NOX)
complex in cross-presentation41, we set out to determine
cellular ROS levels following SBA exposure. Employing two
probes for detection of total ROS levels in our DCs (DHR123 and
H2DCFDA), we found that SBA treatment for 5 h (similar to the
exposure time in the cross-presentation assays) did not increase
ROS levels, while the control PMA did (Fig. 2e). Although ceasing
ROS production by co-treatment of the cells with commonly used
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Figure 1 | Saponin-based adjuvants induce cross-presentation in dendritic cells. (a,b) Tetramer staining of OVA speciﬁc T cells in draining lymph nodes,
10 days following s.c. injection of 20mg OVA and/or 30mg ISCOMs (a, vaccination), or 7 days following co-treatment of established B16OVA melanomas
(5–8mm diameter) with in situ tumour ablation and 30 mg peritumourally injected ISCOMs (b, Cryo-ablation). (c,d) In vitro B3Z cross-presentation assays
demonstrating a concentration-dependent increase in cross-presentation of OVA, only when Matrix C ISCOMs was added. GM-CSF-cultured BMDCs were
exposed to the indicated compounds and 80mgml 1 OVA protein for 5 h, washed and co-cultured o/n with B3Z cells, which produce b-galactosidase upon
recognition of the OVA peptide in Kb. Data in (d) are excerpts from larger titrations. For the non-reactive adjuvants the maximum concentration used is
shown (1.5 ml ml 1), for the ISCOMs the concentration shown is 400ngml 1. (e) In vitro cross-presentation after 5 h exposure to 400ngml 1 of various
SBAs or controls. This contains a crude saponin mixture not puriﬁed for immunoactive fractions, commercially available immunoactive saponin fractions
(VX, SS and FC) and ISCOM structures made with these saponins according to an ‘open access’ protocol. Passive peptide loading with OVA Kb peptides
was used to demonstrate viability and/or equal MHC-I levels. Similar results were obtained in two to three independent experiments. Statistical analysis
was done using a one or two-way ANOVA with post hoc Bonferroni or Tukey tests.
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Figure 2 | SBA-induced cross-presentation is independent of co-stimulation or ROS. (a) FACS analysis of surface markers CD206 (mannose receptor),
MHC-I, and MHC-II. GM-CSF BMDCs were exposed for 5 h to ISCOMs or medium, and processed for FACS staining. Open black lines represent the
corresponding isotype controls. Filled grey lines show the medium-treated cells, while the open red lines are the ISCOM treated samples. (b) FACS analysis
of DC maturation markers CD80 and CD86 after 18 h stimulation with ISCOMs or 1 mgml 1 CpG. (c) Bone-marrow of indicated knockout mice was used to
generate GM-CSF BMDCs. Cells were exposed for 5 h to medium or ISCOMs, washed and co-cultured o/n with B3Z cells. External peptide pulsing
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incubated for 45min before analysis by FACS. (f) In vitro cross-presentation in the presence of NADPH oxidase inhibitors. Indicated compounds and
concentrations were added during the 5 h exposure period to ISCOMs. (g) In vitro cross-presentation using Gp91phox / bonemarrow DCs. Data in
(e) represent single values in titration, whereas the other data show means from triplicates with s.e.m. Data are representative ﬁgures from two to three
individual experiments. Statistical analyses were performed using two way ANOVA with post hoc Bonferroni tests.
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concentrations of the NADPH oxidase inhibitor DPI initially
seemed to abrogate the SBA-induced cross-presentation, the
peptide control revealed lowered MHC-I expression due to
decreased cell viability or down regulation (Fig. 2f). Three
alternative NADPH oxidase inhibitors and various ROS
scavengers did however not interfere with SBA-induced
cross-presentation (Fig. 2f; Supplementary Fig. 5). Finally, SBAs
could normally induce cross-presentation in DCs deﬁcient in
the ROS-inducing NOX2 complex component Cybb (GP91phox)
(Fig. 2g).
Altogether these data do not support a signiﬁcant role for ROS
in the induction of cross-presentation by SBAs.
SBAs induce lipid bodies in parallel with cross-presentation.
Bougneres et al.31 previously demonstrated a relationship
between cross-presentation in DCs and the lipid body-residing
molecule IGTP. This prompted us to examine the presence of LBs
in DCs exposed to various non-microbial adjuvants. To this end,
we stained cells with the neutral lipid dye Bodipy493/503. Strikingly,
SBAs (FC saponin, ISCOMs) appeared to increase the number
and the brightness of cytosolic LBs as determined by confocal
microscopy (CLSM), always in perfect correlation with cross-
presentation levels (Figs 1d and 3a,b). Co-staining for the LB
protein ADRP conﬁrmed that the detected lipid aggregates were
LBs (Fig. 3c). Other adjuvants like AlPO4, non-immunogenic
crude saponin or OVA alone could not elevate the number of LBs
(Fig. 3b). A time course demonstrated that the numbers of LBs per
cell increased linearly over the ﬁrst 32h, which again strongly
correlated with cross-presentation levels (Fig. 3d–f). Control
experiments conﬁrmed that the saponins, but not the ISCOM
particle stabilizing component cholesterol represent the active
moiety inducing LBs, and that mice deﬁcient for Tlr4, Nlrp3 or
Ifnar had a normal ability to generate LBs following SBAs
(Supplementary Fig. 6).
Together, these results suggest that GM-CSF DCs in vitro
possess the striking ability to induce LBs following treatment with
SBAs, which is tightly correlated with the ability to cross-present
soluble antigen.
LB formation and cross-presentation in DCs in vivo. To
determine whether in vivo vaccination with SBAs also resulted in
LB formation in cross-presenting DCs, we co-injected mice with
ISCOMs and OVA. Twelve hours post-injection draining lymph
nodes (LNs) were isolated and subjected to CD11cþ magnetic
bead sorting to isolate all DCs (Fig. 3g). Similarly, DCs were
isolated from B16OVA tumour bearing mice after cryo-ablation
treatment with SBA co-injection (Fig. 3h). Assaying the isolated
CD11cþ DC using two cross-presentation read-outs demon-
strated that ISCOMs efﬁciently induced cross-presentation in DCs,
but not the CD11c negative fraction. Evaluation of the LB content
by CSLM (Fig. 3i, left) and FACS (Fig. 3i, right) showed that also
after in vivo SBA vaccination the number of LBs increased.
SBA sensitivity is a unique feature of monocytic CD11bþ DCs.
DCs can be differentiated in vitro from BM precursors using
GM-CSF or Flt3-L. Remarkably, we found that only DCs
generated with the growth factor GM-CSF, and not DCs cultured
with Flt3-L, were able to cross-present antigen after SBA exposure
(Fig. 4a). Increasing exposure time or dose could not change the
observed cell speciﬁcity (Supplementary Fig. 7). Importantly, Flt3-
L DCs readily activated B3Z cells after external pulsing with OVA
Kb peptide (Supplementary Fig. 7b). Moreover, in these cells
CD206 and MHC-I expression, and ovalbumin uptake were not
inﬂuenced by the SBAs (Supplementary Fig. 7c). In line with the
inability to cross-present antigen upon SBA exposure, the
Flt3-L-generated DCs were incapable of inducing LBs (Fig. 4b),
even at longer exposure times.
The BM cultures with Flt3-L or GM-CSF both give rise to a
complex set of DC subpopulations each arising from predeter-
mined precursors present in the starting population42–44.
The observation that only 45% of the in vitro generated
GM-CSF DCs contained LBs prompted us to purify the different
DC subsets using ﬂowcytometry, and to test their response to
SBAs. First, Flt3-L DCs were sorted based on Naik et al.43 (Fig. 4c).
In the three resulting DC subpopulations no population capable
of cross-presenting OVA upon SBA exposure could be
detected (Fig. 4d). GM-CSF DCs were sorted based on Helft
et al.42, with modiﬁcations (Fig. 4e). Strikingly, only the
CD135 (Flt3) negative DCs (MHCIIloCD11bhiCD115hiCD135neg
and MHCIIintCD11bintCD115intCD135neg subpopulations)
could efﬁciently cross-present OVA in response to SBAs,
whereas the CD135 positive DCs (MHCIIhiCD11bint
CD115lowCD135pos subset) could not (Fig. 4f). Since the
MHCIIintCD11bintCD115intCD135neg cells are considered
multipotent intermediates42, we focused on the two differentiated
DC populations. Again, SBA-mediated induction of lipid bodies
only occurred in the DC subset cross-presenting antigens
due to SBAs: at least 80% of the MHCIIloCD11bhi
CD115hiCD135neg DCs now contained LBs after 5 h (Fig. 4g).
These SBA responsive DCs were previously shown to be derived
from monocytic precursors42. As apparently the monocytic
precursors in the Flt3-L culture did not yield SBA responsive
DCs, the Flt3-L culture was supplemented with GM-CSF for the
last two days. Strikingly, the Flt3-L DCs now acquired full ability to
cross-present antigens in response to SBAs (Fig. 4h). Sorting
experiments conﬁrmed that CD11bþ (Sirpaþ ) DCs, but not the
CD8aþ (CD24þ ) DCs, were responsible for SBA-induced
cross-presentation (Fig. 4i; Supplementary Fig. 8). Similarly,
analysis of pDCs, and CD8aþ or CD11bþ cDCs from
Flt3-L cultures that were ﬁrst sorted and then individually
exposed to GM-CSF conﬁrmed that only the CD11bþ DCs
gained the capacity to respond to SBAs (Fig. 4i). Stainings for the
monocytic marker CD115 showed increased presence of CD115þ
cells among the SBA-responsive CD11bþ DCs following GM-CSF
exposure (Supplementary Fig. 8).
Collectively, these results deﬁne GM-CSF-sensitized CD11bþ
DCs, presumably from monocytic origin, to be the only cells
responsive to SBAs.
Only monocytic CD11bþ DCs respond to SBAs in vivo. Next,
we determined whether the selective SBA responsiveness of
in vitro cultured DCs also exists in vivo. CD8aþ and CD11bþ
DCs sorted from naive spleens based on the markers CD24,
Sirp-a, CD115 and CD4 (Fig. 5a)36, could not cross-present OVA
upon SBA exposure but efﬁciently presented externally loaded
control peptides (Fig. 5b). This is not unexpected as no CD115
staining was observed on these CD11bþ DCs, indicating the
absence of cells from monocytic origin, shown to be responsive to
SBA in vitro (Fig. 5a). Therefore, resident and migratory
CD8aþ , CD103þ or CD11bþ DCs were sorted from naı¨ve
LNs (Fig. 5c)21. Subsequent exposure to SBAs demonstrated that
LN resident, but especially the LN migratory CD11bþ DCs, were
capable of cross-presenting OVA (Fig. 5d). The ability to respond
to SBAs coincided with the presence of cells expressing the
monocytic markers CD14 and Ly6C within the resident, but
especially the migratory CD11bþ DCs (Supplementary Fig. 9).
To evaluate a situation with a high monocytic inﬂux, we analysed
mice bearing Flt3-L excreting tumours to provoke expansion of
endogenous DCs, including pDCs, in an activated environ-
ment45,46. From the tumour-draining LNs we isolated the pDC
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fraction, a fraction containing all CD8aþ LN-resident DCs, and
the CD11bhi DC fraction, and exposed them in vitro to SBAs
(Fig. 5e). Clearly, only the CD11bhi DC fraction was able to cross-
present OVA upon SBA exposure (Fig. 5f). As expected, these
DCs were also the only cells that contained LBs after SBA
treatment (Fig. 5g). Additional FACS analysis of MHC-II levels
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showed that these cells were highly activated, making it difﬁcult
to discriminate migratory from resident CD11bþ cells within
this gate (Fig. 5e). As an additional control, we showed that the
CD8aþ DC containing fraction was able to cross-present OVA
incorporated in nanoparticles, as shown previously (Fig. 5f).
Finally, we sorted cells from mice treated by in situ tumour
ablation with co-injection of the TLR9 ligand CpG-ODN. This
procedure induces the inﬂux of fresh (inﬂammatory) monocytes
into the LNs, but not pDCs like with the Flt3-L excreting
tumours. Similar to our former ﬁndings, only the CD11bhi DCs
could react to SBAs (Supplementary Fig. 10).
Thus, also in vivo monocytic CD11bþ cells uniquely harbor
the ability to cross-present soluble antigens and to induce LBs
upon exposure to SBAs.
SBA-induced lipid bodies are critical for cross-presentation. To
investigate whether a causal relationship exists between LBs and
cross-presentation, we searched for ways to cease LB formation.
Blocking formation of triacylglycerol, fueling the LBs, by inhibiting
the rate-limiting enzymes acyl-CoA, diacylglycerol acyltransferase
(DGAT) 1 and 2 or by inhibiting acyl-CoA synthetase (ACS) or
acetyl-CoA carboxylase (ACC), which are further upstream in lipid
synthesis, all abrogated LB formation (Fig. 6a)31,47,48. Importantly,
inhibiting LB formation also ended the SBA dependent capacity of
DCs to cross-present antigen (Fig. 6b). Viability of the cells and
MHC-I levels were not affected as conﬁrmed by external peptide
loading (Fig. 6b). To further strengthen these ﬁndings, and to
exclude off-target effects of pharmacological inhibition we made
use of bone-marrow DCs derived from IGTP knockout mice,
having a reduced capacity to generate functional LBs31. To screen
for LB induction in a higher number of cells, we established a
FACS-based protocol (Fig. 6c). As expected, Igtp / DCs had
signiﬁcantly less LBs compared with wild-type mice (Fig. 6d).
Although Bougneres et al. showed that IFNg increases expression
of IGTP, and likely ampliﬁes the molecular effects of a deﬁciency
in IGTP31, the SBA-induced difference was not signiﬁcantly more
apparent when cells were co-treated with IFNg. Consistent with
1
2
3
4
100 101 102 103 104 100
100
101
102
103
104
100
101
102
103
104
101 102 103 104
CD
24
2: CD11c+B220–
Sirp a
0 – 3
4 – 10
11 – 80
MHCIIlo
CD11bhi
MHCIIhi
CD11bint
Ce
lls
 c
on
ta
in
in
g
lip
id
 b
od
ie
s 
(%
) 100
80
60
40
20
0
Me
d
ISC
OM
s
Me
d
ISC
OM
s
Medium
MHCIIlo
CD11bhi
MHCIIhi
CD11bint
ISCOMs
Flt3L culture Medium
ISCOMs
OVA peptide
Plasmacytoid DCs:
CD11cpos B220pos
CD8α + cDCs:
CD11cpos CD24hi Sirpaneg
CD11b+ cDCs:
CD11cpos CD24int Sirpapos
0.8
0.6
0.4
0.2
0.0
CD
8α
+ 
cD
Cs
pD
Cs
CD
11
b+
 cD
Cs
La
cZ
 p
ro
du
ct
io
n 
by
B3
Z 
(O
D 5
95
)
Li
fe
ga
te
Si
ng
le
ts
1: CD11c+
1 2
3
4
63.8
2: MHCIIlo
CD11bhi
3: MHCIIint
CD11bint
4: MHCIIhi
CD11bint
Medium
ISCOMs
OVA peptide
MHCIIlo CD11bhi:
MHCIIlo CD11bhi CD115hi CD135neg
MH
CII
lo  C
D1
1b
hi
MH
CII
int  C
D1
1b
int
MH
CII
hi  C
D1
1b
int
MHCIIint CD11bint:
MHCIIint CD11bint CD115int CD135neg
MHCIIhi CD11bint:
MHCIIhi CD11bint CD115low CD135pos
1.5
1.0
0.5
0.0La
cZ
 p
ro
du
ct
io
n 
by
B3
Z 
(O
D 5
95
)
GM-CSF culture
Medium
ISCOMs
400 ng ml–1
ISCOMs
800 ng ml–1
*** ***
1.0
0.8
0.6
0.4
0.2
0.0
Flt3-L
DCs
La
cZ
 p
ro
du
ct
io
n 
by
B3
Z 
(O
D 5
95
)
48
h 
m
ed
iu
m
48
h 
G
M
-C
SF
G
M
-C
SF
 D
Cs
Medium ISCOMs OVA pept
La
cZ
 p
ro
du
ct
io
n 
by
B3
Z 
(O
D 5
95
)
72 h GM-CSF > sort
NS NS
***
***
sort > 72 h GM-CSF/Flt3-L
pD
Cs
CD
8α
+
 D
Cs
CD
11
b+
 D
Cs
pD
Cs
CD
8α
+
 D
Cs
CD
11
b+
 D
Cs
pD
Cs
CD
8α
+
 D
Cs
CD
11
b+
 D
Cs
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
GM-CSFFlt3-L
CD11c
B2
20
0
50
 K
10
0 K
15
0 K
25
0 K
20
0 K
0
102
103
104
105
SSC
102
102
103
104
105
0
0
103 104 105 1020 103 104 105 1020 103 104 105 1020 103 104 105
MHCII CD135
CD
11
c
CD
11
b
102
103
104
105
0
102
103
104
105
0
102
103
104
105
0
CD
11
5
a c d
e f
g h i
Medium
Medium
ISCOMs
M
ed
iu
m
IS
CO
M
sFlt3-L BMDC
D
ap
i
Bo
di
py
49
3/
50
3 Flt3-L DC
nr. of LBs per cell
0 – 3 4 – 10
11 – 80
100
50
0
ISCOMs
Pe
rc
en
ta
ge
 o
f c
el
ls
***
La
cZ
 p
ro
du
ct
io
n 
by
B3
Z 
(O
D 5
95
)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
FI
t3
L 
DC
G
M
CS
F 
DC
b
n.d.
Li
fe
ga
te
Si
ng
le
ts
Figure 4 | Responsiveness to SBAs in vitro is unique to CD11bþ DCs with monocytic origin. (a) In vitro cross-presentation assay using GM-CSF-
or Flt3-L-propagated DCs. (b) Confocal images with LB quantiﬁcations from Flt3-L-generated BMDCs exposed for 5 h to medium or ISCOMs. (c) Gating
strategy of Flt3-L DCs. Sorted populations are gate 1 (pDCs), gate 3 (CD8aþ DCs) and gate 4 (CD11bþ DCs). (d) In vitro cross-presentation assay using
the populations as sorted under c. (e) Gating strategy of GM-CSF DCs. Sorted populations are gate 2 (MHCIIlo CD11bhi), gate 3 (MHCIIint CD11bint) and
gate 4 (MHCIIhi CD11bint). (f) In vitro cross-presentation assay using the populations as sorted under e. (g) CLSM image and LB quantiﬁcation of
populations as sorted under e, after 5 h exposure to ISCOMs or medium. (h) In vitro cross-presentation assay on Flt3-L- or GM-CSF-cultured bonemarrow
DCs. In the 10 day Flt3-L cultures, medium was supplemented for the last 48 h with 20 ngml 1 GM-CSF or medium. (i) In vitro cross-presentation assays
on Flt3-L-cultured DCs, receiving GM-CSF for 72 h after the end of culture. In the left panel the entire day 10 cultures were supplemented with GM-CSF for
another 72 h, after which the resulting populations were sorted (Supplementary Fig. 8). In the right panel the day 10 cultures were sorted, after which the
individual populations were treated with fresh Flt3-L or GM-CSF. All data were reproduced in two to three independent experiments. Statistical analyses
were performed using two-way ANOVA with post hoc Bonferroni tests.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13324 ARTICLE
NATURE COMMUNICATIONS | 7:13324 | DOI: 10.1038/ncomms13324 |www.nature.com/naturecommunications 7
the diminished LB levels, cross-presentation levels were reduced in
the Igtp / cells, conﬁrming the vital role for LBs in SBA-
induced cross-presentation (Fig. 6e). This effect was not related to
altered MHC-I or CD206 expression by DCs, or OVA processing
(Supplementary Fig. 11). To validate the essential role of LBs in the
observed processes, we analysed Adrp / mice also reported to
have reduced functional LBs31,49. We conﬁrmed the lower LB
contents, and subsequently also found reduced SBA-induced cross-
presentation (Supplementary Fig. 12).
Collectively, these results show that LB formation is essential
for effective SBA-induced cross-presentation in vitro.
Endosomal acidiﬁcation and cytosolic antigen translocation.
Enhanced endosomal antigen translocation to the cytosol has
recently been proposed as a possible mechanism for SBA-induced
cross-presentation35. Still, the position of LBs relative to cytosolic
translocation, and the contribution of each process to SBA-aided
cross-presentation is unclear. To assay endosomal translocation,
SBA-treated DCs received the mitochondrial protein cytochrome c.
Extra-mitochondrial localization of cytochrome c induces
apoptosis, so translocation of endosomal cytochrome c to the
cytosol will lead to reduced metabolic activity in a MTT assay.
This assay, and similar experiments using the plant toxin
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saporin that inactivates ribosomes when cytosolic50, conﬁrmed
that increased cytosolic translocation took place in the presence of
SBAs (Fig. 6f). Blockade of endosomal acidiﬁcation
showed that SBA-induced cytosolic translocation and cross-
presentation were both dependent on low endosomal pH
(Fig. 6g; Supplementary Fig. 13a), while treatment with the
proteasome inhibitor epoxomicin demonstrated that cross-
presentation also critically depended on the proteasome
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(Supplementary Fig. 13b). Strikingly, blockade of endosomal
acidiﬁcation (and thus endosomal escape) did not lower the
numbers of SBA-induced LBs per cell (Fig. 6h). Conversely,
pharmacological interference with LB induction also did not
abrogate endosomal translocation (Fig. 6i).
These data show that SBA-triggered antigen translocation,
but not SBA-induced LB formation, is critically preceded by
endosomal acidiﬁcation, and imply a role for SBA-induced LBs in
facilitating the proteasomal route of cross-presentation.
LBs are vital for SBA-induced cross-presentation in vivo. To
determine if cross-presentation in vivo, as induced by ISCOM
vaccine injection, is LB dependent, we used similar approaches as
in vitro. Cross-presentation of the ISCOMs/OVA vaccine in
Adrp / or Igtp / mice lacking functional LBs was
hampered compared with wild-type mice (Fig. 6j; Supplementary
Fig. 14a). Consistently, injecting the DGAT inhibitors
Xanthohumol or A922500 signiﬁcantly reduced cross-presenta-
tion (Supplementary Fig. 14b). Importantly, OVA Kb peptide
presentation was intact in all cases, proving equal MHC-I levels
and viability of the CD11cþ cells (Fig. 6j; Supplementary
Fig. 14). CD11cþ cell percentage or activation status of these
DCs was similar in these experiments (Supplementary Fig. 15).
Finally, analysis of a mix of LB inhibitors in the in situ tumour
ablation model conﬁrmed that also here the induction of LBs was
essential for the SBA-induced cross-presentation (Fig. 6k).
Collectively, these results uncover a causal connection between
SBA-induced LBs and cross-presentation in vivo, and link for the
ﬁrst time LB formation in DCs to adjuvant-mediated vaccine
efﬁciency.
Discussion
SBAs generate strong Th1-driven cellular and humoral immune
responses in various pre-clinical models and in vaccinated
cancer patients12,37–39. How SBAs facilitate immune responses
to vaccine antigens remains incompletely understood. We now
show that SBAs speciﬁcally enhance antigen cross-presentation
and the induction of LBs in the monocytic CD11bþ DC subset.
Using genetic and pharmacological interference, we demonstrate
that LB induction in DCs is causally related to the SBA-
induced increase in antigen cross-presentation and subsequent
T-cell activation.
Our sorting experiments identify monocytic CD11bþ DCs, as
present in GM-CSF DC cultures in vitro and in LNs in vivo, as the
only cells capable of reacting to SBAs by induction of
cross-presentation and LB formation. Among all individual DC
populations generated in in vitro Flt3-L cultures or isolated from
naive spleens no SBA reactive population could be found,
coinciding with the absence of migratory monocytic cells.
Interestingly, GM-CSF exposure of the Flt3 DC cultures is
required for the monocytic precursors present in these cultures to
respond to SBA. This ﬁnding is in line with GM-CSF (Csf-2)
acting either late in differentiation or activation of monocytic
cells. A previous study by Wilson et al. showing SBA-induced
cross-presentation in the LN migratory DC fraction conﬁrms
our results. However, this study also reported signiﬁcant levels
of cross-presentation in CD8aþ DCs. This discrepancy with
our results could possibly be explained by background cross-
presentation of non-formulated OVA antigen by CD8aþ DCs in
their study. In vivo SBA vaccination furthermore will
induce inﬂammation, inﬂuencing co-stimulatory signals on DCs
and subsequent activation of the OT-I T cells used in the
Wilson study. Our B3Z cells react co-stimulation independent
which avoids such activation biases. Earlier studies in human
DCs demonstrated that SBA vaccination with the cancer
antigen NY-ESO-1 induces cross-presentation by myeloid DC,
such as MoDC51. Our preliminary data show LB induction in
these human moDCs generated in the presence of GM-CSF,
linking SBA-induced cross-presentation and LB formation also in
the human context.
Thus, SBAs act to induce potent cross-presentation and LB
induction in monocytic CD11bþ DCs, a population of DCs
distinct from the well-described CD8aþ cross-presenting DC.
Together with the reported increase of CD11bþ DCs at SBA
vaccination sites, this may well explain the efﬁcient cross-priming
of CD8þ T cells by SBA vaccines.
Despite the importance of cross-presentation in health and
disease, the underlying molecular processes are still poorly
understood. Studies so far indicate two main pathways: the
‘cytosolic’ and the ‘vacuolar’ pathway52. Low proteolytic activity
of the endocytic pathway and endosomal stress resulting in
ROS production by the NADPH oxidase complex 2 (NOX2),
have shown to be imperative for efﬁcient cross-presentation of
CD8aþ DCs41. Our cross-presentation studies use a short time
of SBA exposure (1 to 5 h), and in this timeframe no role for ROS
could be detected. Our translocation studies show that
SBAs facilitate endosomal escape, and that this is essential for
cross-presentation. However, since not all pore-forming saponins
show adjuvant activity, and SBA activity is critically dependent on
DCs, other mechanistic elements must be involved as well. Here,
the presence of LBs appears to be equally essential for
cross-presentation, although LBs seem to be dispensable for
endosomal escape of antigens, and vice versa. The observation
that both SBA-triggered processes can be uncoupled at the level of
the endosome makes it unlikely that LBs alter the phagosomal
environment in any direct manner, as also put forward by
Bougneres et al.31
Various types of (metabolic) stress can lead to the induction of
LBs. TLR ligands were shown to increase glycolysis that fueled the
Figure 6 | SBA-induced cross-presentation is dependent on LB formation. (a) LB quantiﬁcation as measured by CLSM in cells treated for 5 h with the
indicated LB inhibitors: (Xanthohumol: 85mM, A922500: 40mM, Triacsin C: 10 mM, TOFA: 120mM). (b) In vitro cross-presentation assays in the presence
of the indicated LB inhibitors (inhibited enzymes in brackets). (c,d) Flowcytometry-based analysis of LB content. Wild-type (c), or Igtpþ /þ and Igtp /
(d) BMDCs were exposed to 800ngml 1 non-immunoactive saponin, FC saponin, ISCOMs or 250ngml 1 IFNg for 5 h, washed, and stained with
Bodipy493-503. (e) In vitro cross-presentation assay using IGTP knockout DCs. (f) Metabolic activity/viability (MTT) assay used to demonstrate cytosolic
translocation of indicated toxins. (g) MTT assay showing endosomal acidiﬁcation is needed for cytosolic translocation. Baﬁlomycin A1, (at 100 nM) is an
inhibitor of endosomal v-ATPase, and thus endosomal acidiﬁcation. (h) Quantiﬁcation of LB induction in the presence of ISCOMs and Baﬁlomycin A1.
(i) MTT assay showing that inhibition of LB induction does not abrogate cytosolic translocation. During the exposure to ISCOMs/Cyt C, the LB inhibitors
TOFA (120mM) and A922500 (60mM) were added. (j) In vitro OT-I cross-presentation assay on isolated LN DCs from OVA protein or peptide-vaccinated
wild-type, Igtp / , or Adrp / mice. (k) B16-OVA tumour bearing mice were treated with cryo-ablation, directly followed by peritumoural injection of
30mg ISCOMs. A mixture of xanthohumol (500mg) and A922500 (150mg) was injected peritumourally, four hrs before ablation and directly after the
ablation. 12 h later, draining LN CD11cþ cells were isolated that entered the cross-presentations assays. LacZ content in B3Z cells was analysed after 2
days. All data represent means with s.e.m., except for d where data represent mean MFI values normalized to medium values. Similar data were obtained in
two to three independent experiments. Statistical analyses were done using ANOVA with post hoc Bonferroni tests.
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de novo synthesis of fatty acids in LBs, essential for TLR
ligand-induced DC activation53. Also other studies have
correlated DC activation status with lipid content: When fatty
acid synthesis of high-lipid-containing DCs was inhibited, these
DCs lost their immunostimulatory phenotype54. Likewise, the
presence of oxidized lipids in LBs was shown to hamper DC
functionality and antigen presentation abilities55. This suggests
that not only the absolute lipid content of LBs in DCs, but also
the composition of the LBs involved can modulate immune
responses. In our hands, feeding DCs fatty acids like oleic acid did
induce LBs, but not cross-presentation (Supplementary Fig. 16).
Finally, the presence of an established tumour (for example,
before cryo-ablation) is sufﬁcient to change the LB proﬁle of
tumour resident DCs/monocytes. This complicates a solid
analysis of LB induction due to SBA administration following
ablation. Together, these data imply that not all LBs are
functionally equal, and that various LB types may be present at
the same time, in the same cell. The fact that SBAs share the
induction of LBs with certain TLR ligands places these adjuvants
in a peculiar position somewhere in between the microbial and
non-microbial adjuvants. Molecular analysis of the ability of SBAs
to facilitate cross-presentation speciﬁcally in monocytic CD11bþ
DCs via endosomal escape and LB induction will be key to
understand SBA adjuvant activity.
IGTP, an IFN-related GTPase associated with LBs in DCs, was
shown to be important in cross-presentation of OVA coated on
large latex beads31. Deletion of IGTP resulted in reduced
IFNg-induced LB numbers, but it was less established what role
IFNg had in their cross-presentation assays. As our studies use
OVA protein, which in itself is not easily cross-presented, a direct
comparison with the use of latex beads is difﬁcult, but one could
speculate that the relatively large size of the beads leads to
endosomal stress and possibly endosomal rupture. This putative
common factor between SBA- and beads induced cross-
presentation could implicate that LBs may become particularly
important in forced types of cross-presentation.
The data presented here indicate an important role for IGTP
and ADRP in the in vivo cross-presentation of soluble antigens
after vaccination with SBAs. Whether this implicates direct
involvement of these molecules, or that the effects are the indirect
result of reduced LB functioning remains to be determined.
To ﬁnd causal connections at a more detailed level, sub-organelle/
molecular studies using puriﬁed LBs from differentially
treated immune cells are required. An intriguing ﬁnding is that
GM-CSF-cultured DCs and CD11bþ LN DCs are uniquely able
to cross-present antigen upon SBA exposure. It will be important
to explore the molecular basis for this DC subset speciﬁcity,
and how this can be linked to LB formation, antigen
cross-presentation and immune activation.
The SBAs used in our study do not contain any known PRR
ligand, and consistent with this they fail to upregulate
co-stimulatory molecules on DCs in vitro (Fig. 2b and ref. 17).
Moreover, cross-presentation was not hampered in Tlr4 / , or
Myd88 / cells (Fig. 2c). Analysis of cells deﬁcient in type I
IFN or the NLRP3 inﬂammasome showed that these pathways
were not involved either. Interestingly, others repeatedly reported
an in vivo dependency of successful SBA vaccination on MyD88,
while TLR4 and IL-1R seemed dispensable16,17. This suggests that
effective vaccination depends on the in vivo release of endogenous
danger signals or the involvement of indirect cytokine signalling.
IL-18 signalling is involved in indirect NK cell and CTL activation
following vaccination with SBAs16, which could partly explain
the dependency on MyD88, being an adaptor for the IL18
receptor. Importantly, in this study MyD88 deﬁciency had no
in vivo effect on maturation or vaccine antigen cross-presentation
by DCs16. This research connects the initial innate cytokine-
cascade with the adaptive cellular response, but leaves room
for MyD88/TLR independent mechanisms of DC activation and
cross-presentation with an alternative molecular basis.
Cancer vaccines evaluated to date mostly fail to change and
overcome the immunosuppressive microenvironment present
in many solid tumours. Current strategies using SBAs and
cancer antigens (for example, NY-ESO-1) have proven to not
only induce antibody responses, but also robust CD8þ T-cell
expansion17,37. Nevertheless, vaccinations with single injections
of SBA-peptide compositions yielded only modest survival beneﬁt
for patients with established tumours56. Interestingly, when these
vaccines were combined with TLR ligands like CpG-ODN57,58, or
followed up by a boosting regimen59, beneﬁcial correlates of
immunological protection could greatly be improved. We
have previously shown that in situ tumour ablation can
provide a source of (neo)-antigens for the generation of anti-
tumour immune responses, provided that additional immune
stimulation is given33. SBAs appeared to be superior in creating
synergy between the ablation and adjuvant-induced immune
effects, inducing long-lasting tumour-directed immunity11.
This makes tumour ablation with local co-administration of
SBAs a promising treatment strategy to explore further in clinical
settings60. Future studies will have to show whether combinations
of SBAs and TLR ligands are also effective combinations in
ablation settings, and it will be appealing to correlate the clinical
outcome to the presence and composition of LBs.
Collectively, our data shows that SBA-induced LBs
are elementary in the mechanism of SBA adjuvanticity.
Understanding the LB-immune connection in SBA vaccination
will help to design new adjuvants for improvement of (cancer)
vaccines, aiming to enhance cross-presentation and the
subsequent induction of potent anti-tumour CTL responses.
Methods
Mice. Igtp / and Adrp / mice were a kind gift of S. Amigorena (Institut
Curie, Paris), and have been described before61,62. Myd88 / , Tlr4 / and
Trif / mice were a kind gift of S. Akira (Osaka University, Japan). Nlrp3 /
bone-marrow was a kind gift of L. Joosten and T. Kanneganti (Nijmegen, the
Netherlands). Gp91phox / bone-marrow was a kind gift of A. Schreiber
(Berlin, Germany). All experiments using knockouts were performed with þ /þ
littermates on C57Bl/6JRccHsd background, (48 crossings). For Igtp / and
Adrp / mice, a common þ /þ littermate was used (for clarity in those
experiments referred to as wild type). All experiments without knockouts were
performed using female wild-type C57Bl/6JRccHsd mice purchased from Charles
River (Sulzfeld, Germany), and were used as 7–11 weeks old animals. C57Bl/6
OT-IxCD90.1þ (Thy-1.1) and C57Bl/6 OT-II mice were held in the Nijmegen
Animal facility. All mice were maintained on standard lab chow and sterile
water, and housed under speciﬁc pathogen-free conditions in IVC cages at the
Nijmegen Animal facility. All animal experiments were approved by the Animal
Experimental Committee of the Radboud UMC, and were performed in accordance
with institutional, national and European guidelines.
Cells. Primary cultures of bone-marrow-derived dendritic cells (BMDCs)
were generated by culturing total bone marrow cells in complete medium
(Roswell Park Memorial Institute (RPMI) medium (Gibco), 10% fetal calf serum
(FCS), 1% L-alanyl-L-glutamine, 0.1% b-mercapto-ethanol and 1% antibiotics/
antimycotics (AA, Gibco)), containing 20 ngml 1 granulocyte-macrophage colony
stimulating factor (GM-CSF DCs, culture 7 days), or containing 200 ngml 1
Fms-related tyrosine kinase 3 ligand (Flt3-L DCs, culture 10 days), as adapted from
previously described protocols63,64. GM-CSF and Flt3-L were purchased from
Peprotech (Rocky Hill, CT, USA). In some experiments the Flt3-L cultures were
supplemented with 20 ngml 1 GM-CSF for the indicated periods. Ex vivo DCs
were isolated from pooled superﬁcial inguinal and axillary lymph nodes, or spleens,
according to previously published protocols, as indicated. For some of these
experiments, mice were injected before with a B16-F10 melanoma expressing
Flt3-L to expand endogenous DC pools, as described before34,45. B16-Flt3-L cells
were cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) supplemented
with 5% FCS and 1% AA, and 5 106 cells were injected s.c. to establish
Flt3-L-producing tumours in 9–12 days. Sorting of DC populations was performed
after incubation in serum-free medium containing collagenase (Worthington,
Lakewood, NJ, USA) and DNAse I (Roche) at 37 C, later supplemented with 1mM
EDTA. For isolation of total CD11cþ fractions, a magnetic bead kit was used
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according to manufacturer’s instructions (Clone N418, Miltenyi Biotech, Bergisch
Gladbach, Germany). For isolation of DC subsets, total cell suspensions were sorted
on a FACS Aria system (BD biosciences), based on the markers as indicated in the
ﬁgures. Purity (498%) and additional markers were conﬁrmed using a FACS Cyan
system (Beckman Coulter). CD8þ T cells speciﬁc for the OVA257-264 SIINFEKL
peptide in an H-2Kb MHC-I context, or CD4þ T cells speciﬁc for the
OVA323-339 peptide in an H-2IAb MHC-II context, were obtained from pooled
spleen and lymph nodes of OT-IxCD90.1 or OT-II transgenic mice, respectively.
Before use, both cell types were puriﬁed by magnetic bead sorting (positive
selection on CD8, Miltenyi). B3Z cells were cultured in Iscove’s Modiﬁed
Dulbecco’s Medium (IMDM) supplemented with 5% FCS, 0.1% b-mercapto-
ethanol, 1% antibiotics/antimycotics, 500 mgml 1 hygromycin. The murine
melanoma cell line B16F10 (ATCC) was cultured in complete medium (MEM, 5%
fetal bovine serum (Greiner Bio-one), 100Uml 1 penicillin G sodium and
100mgml 1 streptomycin (Pen/Strep), MEM sodium pyruvate (1mM), NaHCO3,
MEM vitamins, MEM non-essential amino acids (all from Gibco), 20 mM beta-
mercaptoethanol). OVA-transfected B16F10 (B16OVA, clone MO5) was cultured
in complete medium supplemented with 30 mgml 1 hygromycin and 1mgml 1
G418. B6MECsigOVA cells are transfected with murine B7.1, H-2Kb, and a
construct expressing an ER targeting signal sequence, followed by the
OVA257–264 CTL epitope SIINFEKL (original name B6-B7.1-sigOVA65). These
cells were cultured in IMDM with 5% FCS, 1% L-alanyl-L-glutamine, 0.1%
b-mercapto-ethanol, 1% antibiotics/antimycotics, 100 mgml 1 Hygromycin, and
100mgml 1 G418. All cell-lines in our study were tested mycoplasma negative.
Antibodies and reagents. For FACS experiments the following antibodies
(clone name in brackets) conjugated to various ﬂuorophores were used, together
with corresponding isotypes. All antibodies were used in a 1:400 dilution in PBA,
unless otherwise stated after the clone name. Anti-CD206 (C068C2; 1:100)
(AbD Serotec); anti-CD8a (53-6.7), anti-CD8b.2 (53-5.8; 1:100), anti-CD11c
(HL3), anti-CD69 (H1.2F3), anti-CD135 (A2F10.1; 1:100), anti-CD172 (P84),
anti-Ly6C (AL21), anti-B220 (RA3-6B2; 1:100) (all BD Biosciences); anti-CD14
(Sa2-8; 1:800), anti-CD90.1-Biotin (HIS51), anti-CD115 (AFS98; 1:200), anti-I-Ab/
I-Eb (M5/114.15.2; 1:800), anti-SiglecH (eBio440c; 1:100) (all eBiosciences);
anti-CD4 (RM4-5), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD24 (M1/69),
anti-CD44 (IM7; 1:1,000), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD103
(2E7; 1:800), anti-H-2Kb/Db (28-8-6) (all Biolegend); streptavidin-Alexa488, -555,
-647 (Invitrogen; 1:800). All stainings were preceded by blocking Fc receptors
using anti-CD16/CD32 antibodies (BD; 1:800). For confocal experiments the fol-
lowing antibodies/reagents were used: chicken anti-mouse/human ADRP (Abcam;
5 mgml 1), Goat anti-chicken IgY-DyLight549 (Abcam; 5 mgml 1), Bodipy493-503
dye (Invitrogen), and DAPI dye (Sigma, St Louis, MO, USA). Various assays were
done in the presence of the following inhibitors or ROS scavenging compounds:
diphenyleneiodonium chloride (DPI) and Baﬁlomycin A1 were purchased from
EMD Millipore (Billerica, MA, USA); acetovanillone (Apocynin), L-ascorbic acid
(Ascorbic acid), 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid
(Trolox, a vitamin E analog), N-acetyl- L-cysteine (LNAC), DGAT-1 speciﬁc
inhibitor A922500, chloroquine, and epoxomicin all were from Sigma; DGAT 1/2
inhibitor xanthohumol was from Tocris Biosciences (Bristol, UK); Triacsin C was
from Enzo Biochem (Farmingdale, NY, USA); 5-Tetradecyloxy-2-Furoic Acid
(TOFA), N-([3-(Aminomethyl)phenyl]methyl)ethanimidamide dihydrochloride
(1,400W), and 2-Cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester,
bardoxolone Methyl (CDDO-me) were from Cayman Chemical (Ann Arbor,
USA); Murine IFN-gamma was from Peprotech. Water-soluble cholesterol, PMA
and cis-9-octadecenoic acid (Oleic acid) were from Sigma. Ovalbumin conjugated
to various alexa dyes was obtained from Invitrogen, double quenched (DQ)-OVA
was purchased from ThermoFisher Scientiﬁc. Cytochrome C from equine hearth
was purchased from Sigma. Saporin from Saponaria ofﬁcinalis L (a kind gift
from M. Thakur), is a type I RIP that is internalized by receptor-independent
endocytosis and accumulates in late endosomes and lysosomes66. Type I RIPs
and cytochrome C can only exhibit cytotoxicity if they can efﬁciently escape from
the endo/lysosomes.
Adjuvants. CpG 1668 (50-TCCATGACGTTCCTGATGCT-30) with total
phosphorothioate-modiﬁed backbone was purchased from Sigma. The following
non-microbial adjuvants were used (all MSD Animal Health, Boxmeer, the
Netherlands): 45/55 w/w water-in-oil emulsion using Miglyol 840 and 0.5% w/w
Arlacel P135; MF59 oil-in-water emulsion using squalene; Aluminum phosphate
0.75% in phosphate buffer. All adjuvants were tested in a large titration in the B3Z
assays. As saponin-based adjuvants (SBAs) the Quillaja saponaria-derived adju-
vants Matrix C ISCOMs (MSD) and Quil A saponin (MSD) as indicated were used.
As a control, Quillaja saponaria-derived saponins not puriﬁed for immunoactive
fractions were obtained from Sigma (‘crude saponin’). Next to the proprietary
made Matrix C, ISCOM structures were used produced via an open access
method40. In short, three immunoactive saponin fractions ‘Supersap (SS)’,
‘Vaxsap (VX)’ and ‘Fraction C (FC)’ were obtained from Desert King International
(San Diego, US). Fifty milligram SS or FC saponin was slowly dissolved in milli-Q
water to obtain 100mgml 1. Next, 1 gram n-(D-glucityl)-n-methyldecanamide-n-
decanoyl-n-met (Mega10) was dissolved in MilliQ to obtain a 20% (w/w) solution.
This solution was used to dissolve 50mg cholesterol (Sigma) and 50mg
phosphatidyl choline S (Lipoid, Germany). At a temperature of 25.5 C, the
saponins were added to 1ml of chol/pc mixture. After adjusting the cholesterol
concentration to 1mgml 1 by adding PBS, the mixture was incubated overnight
in a shaker at 25.5 C, and subsequently dialysed against PBS. ISCOMs structures
of±40 nm were conﬁrmed by bringing the solution onto a carbon-coated formvar
plasm grid, which was activated with a 1% uranylacetate solution, and analysed
using a Versa 3D electron microscope. Saponin content was analysed with an
HPLC reversed phase system (Thermo RSLC 3000), using a Supersphere 60 RP
select B column, and an acetonitrile/water/TFA gradient.
Flow cytometry. Phenotypic characterization of DCs and T cells was performed
using standard antibody staining protocols, and analysis was done using a FACS
Cyan (Beckman Coulter) or a FACS Verse system (BD). All stainings were pre-
ceded by Fc-receptor blockade using anti CD16/32 antibodies. APC maturation
status was evaluated using CD80, IAb or Kb staining after gating on CD11cþ
cells. Receptor expression of CD206 (mannose receptor), Kb levels, OVA uptake
and degradation were used to prove equal abilities of various DCs to internalize,
process and present antigens. For OVA uptake and degradation assays, cells were
incubated for 5 h with 0.25mgml 1 OVA coupled to Alexa647 (Invitrogen) or
with 1.0 mgml 1 double quenched DQ-OVA (which ﬂuoresces once degraded in
the endolysosomal system).
B3Z and OT-I cross-presentation assays. For the cross-presentation assays,
80 103 cells (in vitro BMDCs) or 150 103 cells (ex vivo DCs) were pulsed with
endotoxin-free chicken egg ovalbumin (OVA, Hyglos GmbH, Germany) in the
presence of the indicated adjuvants or inhibitors. Typically, 400 ngml 1 SBAs
were added, and 80 mgml 1 OVA, unless indicated otherwise. After 5 h of
incubation at 37 C, cells were washed and cultured for 18 h with 80 103 B3Z
cells. B3Z cells and positive control B6-B7.1-sigOVA cells were cultured as
described elsewhere67. As a control for cell-viability and/or MHC-I expression
levels, DCs were washed 30min before adding the B3Z cells and pulsed with
5 ngml 1 peptides. Peptides (OVA: SIINFEKL, HPV: RAHYNIVTF, Ad-E1A:
SGPSNTPPEI) were obtained from J.W. Drijfhout (LUMC, Leiden, the
Netherlands). In one experiment standard PEG-ylated PLGA nanoparticles
formulated with OVA were used, which were produced in our lab as described
elsewhere68. The amount of particles was adjusted so that the wells contained an
OVA end-concentration of 30 mgml 1. The presentation by DCs of SIINFEKL
in H-2Kb results in production of b-galactosidase by the B3Z cells65, which
can be detected by adding 0.15mM chlorophenolred-h-D-galactopyranoside
(Calbiochem), 9mM MgCl2, 0.125% NP40, and 100mM b-mercaptoethanol in
PBS. Plates were incubated for 2 to 5 h at 37 C and absorbance values were
measured using a photospectrometer (595 nm).
For the OT-I/II cross-presentation assays 25 103 DCs were plated and treated
as indicated above. Puriﬁed OT-I or OT-II cells (CD8 or CD4 MACS beads) were
labelled with cell-proliferation dyes CFSE or PBSE, according to the manufacturer’s
instructions (Invitrogen), and 50 103 cells were incubated with the DCs for up to
72 h. After one day of incubation, cells were stained with CD90.1, CD8, and the
early activation marker CD69. After 3 days, the late stage activation marker CD44
and CFSE/PBSE dilution was analysed instead. All T-cell analyses were performed
after double gating on CD8b and CD90.1. Cells were measured using a FACS Cyan
(Beckman Coulter) or a FACS Verse system (BD).
Lipid body stainings. Lipid bodies were visualized by CLSM or FACS. For
confocal microscopy, 250 103 DCs were plated for 45min at 37 C on glass
coverslips coated overnight with 20 mgml 1 ﬁbronectin (Sigma). After washing
with PBS, cells were exposed to the indicated treatment conditions in serum-free
medium for 5 h. Typically, 400 ngml 1 SBAs were used, unless otherwise
indicated. Next, cells were ﬁxed in 4% PFA solution in PBS for 15min. For
co-staining for ADRP, ﬁxed cells were permeabilized with 0.1% Saponin (Sigma) in
PBA and incubated with primary antibodies in PBS plus 0.2% BSA/0.05% saponin
for 1 h. Next, cells were washed and incubated with anti-chicken IgY secondary
antibody conjugated to Dyelight549 (Abcam) for 45min. LBs were visualized by
adding Bodipy493-503 probe (Invitrogen) at 7 mgml 1 for 10min. Nuclear
counterstaining was performed with DAPI dye according to the manufacturer’s
instructions. After washing, coverslips were mounted onto the slides using standard
Mowiol sealing. Images were acquired using a Olympus FV1000 confocal laser
scanning microscope (Olympus, Tokyo, Japan) with a 60 1.35 NA Oil immer-
sion objective. Merged images were generated using ImageJ software (NIH,
Bethesda, Maryland). For the counting of LB numbers around 15 images were
taken at random spots in the sample, which were analysed using FIJI software.
Nuclear defragmentation as detected by the DAPI stain was used to exclude
apoptotic cells (o2%), and only cells which were entirely visible in the image were
taken along for counting. LB numbers were counted manually, yielding each time
data of 90–150 cells. For FACS analysis, cells were exposed to the indicated
treatment conditions in 96 well plates for 5 h, washed, and ﬁxated for 10min with
1% PFA. Next, cells were permeabilized using PermWash according to the man-
ufacturer’s instructions (eBioscience). Cells were then incubated with 10 mgml 1
Bodipy493-503 for 30min at 4 C. After washes, Bodipy ﬂuorescence was detected in
the FL1 (488: 530/40) channel on a FACS Cyan system (Beckman Coulter). The
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Bodipy signal integrates info from both the number, size and intensity of LBs
(validated by Gocze et al.69).
ROS detection. The production of total cellular ROS was detected using DHR123
and H2DCFDA. 150 103 GM-CSF cultured BMDCs were plated in serum-free
medium in 96 wells round bottom plates (Costar). Cells were pretreated for 10min
with 0.5 or 50mM dihydrorhodamine 123 (DHR123, Sigma), after which the
following compounds were added: 400 ngml 1 ISCOMs or 1 mgml 1 phorbol
12-myristate 13-acetate (PMA, Sigma). After 15 or 45min incubation, DHR
staining was directly measured by FACS. Similarly, ROS was detected using CM-
H2DCFDA (Invitrogen). For this, cells were washed with HBSS containing
magnesium and calcium, after which they were incubated for 45min with 10 mM
H2DCFDA and the above stimuli dissolved in HBSS buffer.
MTT assays. GM-DCs were seeded in ﬂat-bottom 96-well plates (Costar) at
170 103 cells per well and cultured overnight to adhere. Next, they were exposed
to the indicated compounds for 5 h (ISCOMs: 800 ngml 1, Saporin: 1 nM,
Cytochrome C: 2.5mgml 1). After cells were washed and rested o/n, their
metabolic activity/viability was measured in a standard MTT assay. In short, 10 ml
MTT reagent (4mgml 1) (Sigma) was added in medium. Plates were incubated
for 1–4 h at 37 C after which supernatant was removed and 100 ml lysis buffer
(0.5% SDS, 4% 1N HCl, and 3.5% Milli-Q in isopropanol) was added. After 15min.
of incubation, absorbance was measured at 595 nm. Metabolic activity versus
control was calculated as (treatment—blank)/(control—blank) 100%. Triplicate
wells for each concentration were performed.
In vivo procedures. The in vivo effects of ISCOMs on cross-presentation and LB
induction were analysed in wild-type, ADRP/IGTP knockouts or their þ /þ
controls (n¼ 6). For this, 300 mg endofree OVA protein was injected s.c. on the
femur, together with 30mg ISCOMs and/or LB inhibitors. LB inhibitors (or vehicle)
were injected twice: 4 h before, and together with the OVA/ISCOMs injection
(Xanthohumol: 500 mg per injection, A922500: 150mg per injection). To control for
MHC-I levels and cell viability, 40 mg OVA Kb peptide was injected in control mice.
12 h later, draining lymph nodes were harvested from which a single cell suspen-
sion was made using collagenase/DNAse containing serum-free medium. CD11cþ
fractions were isolated using magnetic bead sorting on CD11c according to the
manufacturer’s instructions. Next, these cells were processed for the B3Z/OT-I
cross-presentation assays and LB stainings similarly as in the in vitro assays, with
one exception: the co-incubation of DCs with B3Z cells was longer (42 instead of
18 h), to allow the B3Z cells more time to produce b-galactosidase.
The cryo-ablation model, in which established tumours are destroyed by
freezing has been described in more detail in the following articles11,33,34. In short,
B16F10 melanomas or B16F10 cells expressing ovalbumin (B16OVA) growing s.c.
on the femur with a diameter of 5–8mm were treated by macroscopically freezing
the entire tumour using a liquid nitrogen-cooled CryoPro Maxi device (Cortex
technologies, Hadsund, Denmark). Directly before ablation, mice received an
intratumoural booster shot with 20 mg OVA, whenever indicated. Directly after
ablation, 30mg ISCOMs or 50 mg CpG, as indicated, was injected in the peri-
tumoural area.
For tetramer detection of speciﬁc T cells in vaccinated or ablated mice, mice
were injected s.c. on the right femur with 20 mg endofree OVA and/or 30mg
ISCOMs, or ablated as described above. Ten days later the draining lymph nodes
(sup. ing.) were harvested from which a single cell suspension was made using
collagenase/DNAse supplemented medium. First, cells were stained for anti
CD8b.2 on ice, after which OVA Kb speciﬁc tetramers (Pelimers; Sanquin,
Amsterdam, the Netherlands) were used to stain for OVA-speciﬁc T cells. Staining
was done according to manufacturer’s instructions, at 37 C, and analysed on a
FACS Calibur system (BD). No randomization of animals or blinding was
performed in these in vivo experiments during the treatment phase, but sample
analysis was performed blinded by coding samples.
Statistical analysis. Depending on the experimental layout, Student’s T test, one-
way ANOVA, or two-way ANOVA was performed with post hoc Tukey or Bon-
ferroni tests, as indicated in the ﬁgure legends. For in vivo data showing biological
replicates sample sizes were computed using a-priori poweranalyses for ANOVA,
using a power of 0.8 and alpha 0.05. Differences were considered signiﬁcant when
P values were smaller than 0.05. In all ﬁgures, results are expressed as mean values
from triplicates with s.e.m., unless indicated otherwise, while the following
symbols were used: *Po0.05; **Po0.01; ***Po0.001; n.s., P40.05; ND¼ not
determined.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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